Working Paper
Authors
- Kaid Harper
AbbVie (United States) ,
- Timothy Grieme AbbVie (United States) ,
- Timothy Towne AbbVie (United States) ,
- Daniel Mack AbbVie (United States) ,
- Moiz Diwan AbbVie (United States) ,
- Yi-Yin Ku AbbVie (United States) ,
- Jeremy Griffin AbbVie (United States) ,
- Robert Miller AbbVie (United States) ,
- En-xuan Zhang Asymchem ,
- Zhi-qing Liu Asymchem ,
- Song-yuan Zheng Asymchem ,
- Ning-ning Zhang Asymchem ,
- Srinivas Grangula Asymchem ,
- Jia-long Yuan Asymchem ,
- Ping-zhong Huang Asymchem ,
- James Gage Asymchem
Abstract
Despite the growth of photoredox methods in academia, application of photoredox at scale in the pharmaceutical and fine chemical industries has been slow. In this report, a photoredox trifluoromethylation of a thiophenol was modified from the original literature report and the mechanism was investigated to define key scale-up parameters. The mechanistic insight was leveraged in the design and execution of two different reactor designs: an LED-based plug flow photoreactor as well as a laser-based continuous stirred tank photoreactor. In one of the first examples of commercial scale photoredox chemistry, the process was scaled to provide over 500 kilograms of the desired intermediate and amended to fully continuous manufacturing.
Content

Supplementary material

Supplemental Information for Commercial-Scale Visible-light Trifluoromethylation of 2-Chlorothiophenol using CF3I gas.
Data supporting the manuscript : Commercial-Scale Visible-light Trifluoromethylation of 2-Chlorothiophenol using CF3I gas.